Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Free Cash Flow: 2018-2025

Historic Free Cash Flow for Neurogene (NGNE) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.

  • Neurogene's Free Cash Flow fell 24.73% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.4 million, marking a year-over-year decrease of 10.64%. This contributed to the annual value of -$71.4 million for FY2024, which is 38.01% down from last year.
  • Latest data reveals that Neurogene reported Free Cash Flow of -$19.6 million as of Q3 2025, which was down 0.26% from -$19.6 million recorded in Q2 2025.
  • Neurogene's Free Cash Flow's 5-year high stood at -$9.4 million during Q2 2023, with a 5-year trough of -$21.8 million in Q1 2024.
  • Over the past 3 years, Neurogene's median Free Cash Flow value was -$17.1 million (recorded in 2023), while the average stood at -$16.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 72.96% in 2024, then climbed by 1.20% in 2025.
  • Over the past 3 years, Neurogene's Free Cash Flow (Quarterly) stood at -$17.1 million in 2023, then dropped by 3.23% to -$17.6 million in 2024, then fell by 24.73% to -$19.6 million in 2025.
  • Its Free Cash Flow stands at -$19.6 million for Q3 2025, versus -$19.6 million for Q2 2025 and -$21.6 million for Q1 2025.